Stanford Alliance Director
Paul Humphries, Ph.D.
Dr. Paul Humphries joined Stanford ChEM-H in 2018 as the Alliance Director of the Stanford Alliance for Innovative Medicines (AIM). Dr. Humphries provides strategic leadership and management of the Stanford AIM program to accelerate the translation of Stanford research into next-generation treatments that impact human health. Dr. Humphries comes to ChEM-H with over 17 years of research and development experience, including leadership of target-based and phenotypic drug discovery programs ranging from target/phenotype identification to Phase 2 clinical trials. He has advanced eight compounds into the clinic. Prior to joining ChEM-H, Dr. Humphries worked as Chief Scientific Officer for Reset Therapeutics where he assumed full responsibility for all aspects of research and nonclinical development and focused on harnessing the power of the body’s internal molecular clocks to discover, develop, and commercialize high-value therapeutics for a variety of disease indications. Prior to this, Dr. Humphries worked at Pfizer on numerous drug discovery programs resulting in seven IND submissions across four late-stage projects and was responsible for numerous go/no go decisions on early stage projects. He has authored approximately 30 scientific articles and patents on a wide range of topics/drug targets. Dr. Humphries received his Ph.D. in organic chemistry from the University of Sheffield, UK and conducted post-doctoral research at Florida State University.
Takeda Alliance Director
Cathy Tralau-Stewart, Ph.D.
Dr. Tralau-Stewart is the Takeda Director of Stanford AIM and Senior Director of Alliances for Takeda Pharmaceuticals. Dr.Tralau-Stewart is responsible for the strategic management of the Takeda collaboration with Stanford & Takeda’s input into the Stanford AIM projects. Dr. Tralau-Stewart has many years’ experience of leading drug discovery programs from target validation through to patients. She is a pharmacologist and has been involved in and led teams, which created over 13 marketed products and many candidate compounds (including Advair, Flixonase, Flixotide, Flovent, Allermist, Bosatria, Ariflo, Zantac (extensions), Avodart, Zofran, Relovar/Breo, Anoro, Avamys). She completed her Ph.D. at University College London and spent nearly 20 years in pre-clinical to clinical drug discovery at GlaxoSmithKline. For the last 10 years Dr. Tralau-Stewart has been leading the development of academic -industry drug discovery at Imperial College London and University of California San Francisco (UCSF). At UCSF she led the successful Catalyst translational program, supporting the development of novel therapeutic, diagnostic, digital health and device products to exits such as licenses, start-up company formation and partnerships. Dr. Tralau-Stewart has authored many peer reviewed publications and patents and been involved in leading the translation towards the clinic of over 30 academic technologies. Dr Tralau-Stewart is a Visiting Scholar at Stanford ChEM-H, Adjunct Associate Professor Bioengineering & Therapeutics at UCSF and serves as a Board Director of Society of Laboratory Automation & Screening (SLAS).